Clinical trials: Lymphoid Neoplasms
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Thiopurine EnhAnced Maintenance Therapy
Acute Lymphoblastic Leukaemia (ALL) is the most frequent cancer in children. The survival rate has improved significantly during the last decades, but the treatment still fails to cure 15 % of the patients.
- Trial name
- TEAM (NCT02912676)
- Testing
- Thioguanine (oral)
- Where
- 4 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- Kjeld Schmiegelow
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01158274
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00003397
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
B-cell Chronic Lymphoid Malignancies Markers
Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated).
- Conditions
- Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia, Mantle Cell Lymphoma
- Trial name
- MALYZOMA-II (NCT04952974)
- Where
- France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Strasbourg, France
Lymphoma
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bleomycin in treating patients with non-Hodgkin's…
- Trial name
- NCT00003110
- Testing
- bleomycin sulfate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Chronic Lymphocytic Leukemia
ALICIA (Acalabrutinib in CLL Therapy)
This is a multicenter non-interventional observational study conducted with a single hand arm to collect real-world data. In this study, commercially available acalabrutinib will be used as prescribed treatment for CLL as per the…
- Trial name
- ALICIA (NCT04746950)
- Where
- 15 sites in Russia
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Lymphoma, Nonhodgkin, Leukemia, Lymphocytic
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
CAR-T therapy is now available as a commercial product for treatment of relapsed /refractory acute lymphoblastic leukaemia and B-lymphoma. There is limited access to this new treatment as the product is very expensive.
- Trial name
- NCT06462248
- Testing
- CUCART19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chi Kong Li
Advanced Cancers, Leukemia
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to find the highest tolerable dose of T cells that can be given in combination with standard chemotherapy to patients with CLL. The safety of this combination will also be studied.
- Trial name
- NCT01653717
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in older adults or younger infirm patients with high-risk hematopoeitic malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00513318
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT02890758
- Testing
- Natural Killer (NK) Cells, ALT803
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brenda Cooper, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01399840
- Testing
- BMN 673
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
Leukemia
Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of theophylline in treating patients who have in situ…
- Trial name
- NCT00003808
- Testing
- theophylline
- Where
- 71 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Methotrexate Induced Nephrotoxicity
Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours Prehydration
Infusions with high-dose methotrexate 5 g/m2 or 8 g/m2 are used to treat children with acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, medulloblastoma and ependymoma.
- Trial name
- NCT00570817
- Testing
- 12 hours of prehydration
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- University of Aarhus
Mechanical Ventilation Complication, Pediatric ALL
Measuring Thickness of the Normal Diaphragm in Children Via Ultrasound.
Critically ill children treated with invasive mechanical ventilation (iMV) in a paediatric intensive care unit (PICU) may suffer from complications leading to prolonged duration of ventilation and PICU stay.
- Conditions
- Mechanical Ventilation Complication, Pediatric ALL, Intensive Care Unit Acquired Weakness
- Trial name
- NCT04589910
- Testing
- diaphragm thickness and thickening fraction
- Where
- Netherlands
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
This is a Phase I, multicenter, open-label, dose-escalation study of polatuzumab vedotin administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory hematologic malignancies.
- Trial name
- NCT01290549
- Testing
- Polatuzumab Vedotin, Rituximab
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Genentech, Inc.
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT05828589
- Testing
- BGB-21447
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- BeOne Medicines
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL)
AZD6738 First Time in Patient Multiple Ascending Dose Study
In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma.
- Conditions
- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
- Trial name
- NCT01955668
- Testing
- Administration of AZD6738
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.